Douglas E Peterson

Summary

Affiliation: University of Connecticut Health Center
Country: USA

Publications

  1. ncbi Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy
    Douglas E Peterson
    Section of Oral Medicine, Department of Oral Health and Diagnostic Sciences, School of Dental Medicine and Program in Head and Neck Cancer and Oral Oncology, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT 06030 1605, USA
    Support Care Cancer 21:327-32. 2013
  2. ncbi Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, 06030 1605, USA
    Support Care Cancer 14:499-504. 2006
  3. ncbi New strategies for management of oral mucositis in cancer patients
    Douglas E Peterson
    Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center, Department of Oral Health and Diagnostic Science, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030 1605, USA
    J Support Oncol 4:9-13. 2006
  4. ncbi Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 1605, USA
    J Clin Oncol 27:4333-8. 2009
  5. ncbi Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center, Farmington, CT, USA
    Support Care Cancer 18:1089-98. 2010
  6. ncbi Supportive care treatment guidelines: value, limitations, and opportunities
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT 06030 1605, USA
    Semin Oncol 38:367-73. 2011
  7. ncbi Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, and Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, Connecticut 06030 1605, USA
    Cancer 109:322-31. 2007
  8. ncbi Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study
    Rajesh V Lalla
    Section of Oral Medicine, Department of Oral Health and Diagnostic Sciences, Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, MC 1605, Room L6062, 263, Farmington Avenue, Farmington, CT 06030, USA
    Support Care Cancer 18:95-103. 2010
  9. ncbi Management of oral mucositis in patients who have cancer
    Rajesh V Lalla
    Division of Oral Medicine, Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center MC 1605, 263 Farmington Avenue, Farmington, CT 06030, USA
    Dent Clin North Am 52:61-77, viii. 2008
  10. ncbi Novel therapies
    Douglas E Peterson
    Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030-1605, USA
    Semin Oncol Nurs 20:53-8. 2004

Detail Information

Publications24

  1. ncbi Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy
    Douglas E Peterson
    Section of Oral Medicine, Department of Oral Health and Diagnostic Sciences, School of Dental Medicine and Program in Head and Neck Cancer and Oral Oncology, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT 06030 1605, USA
    Support Care Cancer 21:327-32. 2013
    ..This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy...
  2. ncbi Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, 06030 1605, USA
    Support Care Cancer 14:499-504. 2006
    ..OBJECTIVES: This paper will review history, current status, and new research directions associated with terminology and assessment of mucosal injury in cancer patients in the context described above...
  3. ncbi New strategies for management of oral mucositis in cancer patients
    Douglas E Peterson
    Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center, Department of Oral Health and Diagnostic Science, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030 1605, USA
    J Support Oncol 4:9-13. 2006
    ..As the understanding of the pathobiology of mucositis improves, clinicians should be able to customize future therapies based on each patients risk for developing the condition...
  4. ncbi Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 1605, USA
    J Clin Oncol 27:4333-8. 2009
    ..This study evaluated the safety and efficacy of recombinant human intestinal trefoil factor (rhITF) administered as topical oral spray for prevention and treatment of chemotherapy-induced oral mucositis (OM)...
  5. ncbi Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center, Farmington, CT, USA
    Support Care Cancer 18:1089-98. 2010
    ....
  6. ncbi Supportive care treatment guidelines: value, limitations, and opportunities
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT 06030 1605, USA
    Semin Oncol 38:367-73. 2011
    ....
  7. ncbi Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, and Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, Connecticut 06030 1605, USA
    Cancer 109:322-31. 2007
    ..The efficacy and safety of Saforis (glutamine) powder in UpTec for oral suspension was evaluated for the prevention and treatment of OM...
  8. ncbi Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study
    Rajesh V Lalla
    Section of Oral Medicine, Department of Oral Health and Diagnostic Sciences, Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, MC 1605, Room L6062, 263, Farmington Avenue, Farmington, CT 06030, USA
    Support Care Cancer 18:95-103. 2010
    ..The objective of this small (n = 3) pilot study was to examine the role of the COX pathway in causing mucosal injury and pain in chemotherapy-induced oral mucositis...
  9. ncbi Management of oral mucositis in patients who have cancer
    Rajesh V Lalla
    Division of Oral Medicine, Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center MC 1605, 263 Farmington Avenue, Farmington, CT 06030, USA
    Dent Clin North Am 52:61-77, viii. 2008
    ..These agents are discussed in the context of recently updated evidence-based clinical management guidelines...
  10. ncbi Novel therapies
    Douglas E Peterson
    Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030-1605, USA
    Semin Oncol Nurs 20:53-8. 2004
    ..IMPLICATIONS FOR NURSING PRACTICE: The oncology nurse plays a pivotal role in assessing and managing mucositis in cancer patients...
  11. ncbi Mucosal damage: a major risk factor for severe complications after cytotoxic therapy
    Douglas E Peterson
    Department of Oral Diagnosis, School of Dental Medicine, Cancer Center, University of Connecticut Health Center, Farmington 06030-1605, USA
    Semin Oncol 31:35-44. 2004
    ....
  12. ncbi A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy
    Rajesh V Lalla
    Section of Oral Medicine and Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT, USA
    Support Care Cancer 20:1797-804. 2012
    ..The objective of this study was to evaluate the efficacy of misoprostol oral rinse in reducing the severity of oral mucosal injury caused by high-dose chemotherapy...
  13. ncbi Oral mucositis: the new paradigms
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine and Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, Connecticut 06030 1605, USA
    Curr Opin Oncol 22:318-22. 2010
    ..This review addresses recent advances regarding mucosal injury in cancer patients, with emphasis on symptom clusters, genetically based tissue susceptibility and risk prediction, imaging technology, and computational biology...
  14. ncbi Treatment of mucositis, including new medications
    Rajesh V Lalla
    Division of Oral Medicine, Department of Oral Health and Diagnostic Sciences and the Head and Neck Oral Oncology Program, Neag Comprehensive Cancer Center University of Connecticut Health Center, Farmington, CT 06030, USA
    Cancer J 12:348-54. 2006
    ..In addition, several agents in clinical development for mucositis are discussed in the context of the current pathobiologic model as well as the recently updated evidence-based clinical management guidelines...
  15. ncbi Oral mucositis
    Rajesh V Lalla
    Division of Oral Medicine, Department of Oral Diagnosis, University of Connecticut School of Dental Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA
    Dent Clin North Am 49:167-84, ix. 2005
    ..This article reviews the current knowledge on the pathogenesis, clinical presentation, diagnosis, and management of oral mucositis...
  16. ncbi Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions
    Andrei Barasch
    Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030 1605, USA
    Oral Oncol 39:91-100. 2003
    ..The current review summarizes these controversies and highlights the need for strategies for stratification of patients enrolled in clinical trials, in relation to both pathophysiologic and associated risk factors...
  17. ncbi Xerostomia--any progress?
    Douglas E Peterson
    Support Care Cancer 11:199-200. 2003
  18. ncbi Evidence-based guidelines for managing mucositis
    Deborah B McGuire
    School of Nursing, University of Maryland, Baltimore, MD 21201, USA
    Semin Oncol Nurs 20:59-66. 2004
    ..When evidence is lacking and guidelines have gaps, nurses can play important roles in research to overcome these gaps...
  19. ncbi Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients
    Stephen T Sonis
    Division of Oral Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 100:1995-2025. 2004
    ....
  20. ncbi Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
    Edward B Rubenstein
    Department of Palliative Care and Rehabilitation Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 100:2026-46. 2004
    ....
  21. ncbi Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital Cancer Centre, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000, Australia
    Support Care Cancer 14:492-8. 2006
    ....
  22. ncbi Visual graphical analysis: a technique to investigate symptom trajectories over time
    Carlton G Brown
    Nurs Res 56:195-201. 2007
    ..Visual graphical analysis (VGA) is a technique that can provide researchers with an alternative method of quantitative statistical analysis that is more sensitive to individual change and variation...
  23. ncbi Updated clinical practice guidelines for the prevention and treatment of mucositis
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
    Cancer 109:820-31. 2007
    ..These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients. Cancer 2007;109:820-31. (c) 2007 American Cancer Society...
  24. ncbi The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients
    Deborah B McGuire
    School of Nursing, University of Pennsylvania, 420 Guardian Drive, Philadelphia, PA 19104, USA
    Cancer Invest 20:893-903. 2002
    ..Provided that clinical examiners have appropriate training and experience, the OMI-20 can be used as a reliable, valid, and quantifiable measure of mucositis in clinical research...